Development of an interpretable machine learning-based intelligent system of exercise prescription for cardio-oncology preventive care: A study protocol

• Published in: Frontiers in cardiovascular medicine Vol. 9; p. 1091885
• Main Authors: Gao, Tianyu, Ren, Hao, He, Shan, Liang, Deyi, Xu, Yuming, Chen, Kecheng, Wang, Yufan, Zhu, Yuxin, Dong, Heling, Xu, Zhongzhi, Chen, Weiming, Cheng, Weibin, Jing, Fengshi, Tao, Xiaoyu
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 01.12.2023
• Subjects: cardio-oncology; exercise prescription; interpretable artificial intelligence; machine learning; physical activity; prescription recommendation; exercise prescription; cardio-oncology; interpretable artificial intelligence; machine learning; prescription recommendation; physical activity
• ISSN: 2297-055X; 2297-055X
• DOI: 10.3389/fcvm.2022.1091885

Cardiovascular disease (CVD) and cancer are the first and second causes of death in over 130 countries across the world. They are also among the top three causes in almost 180 countries worldwide. Cardiovascular complications are often noticed in cancer patients, with nearly 20% exhibiting cardiovascular comorbidities. Physical exercise may be helpful for cancer survivors and people living with cancer (PLWC), as it prevents relapses, CVD, and cardiotoxicity. Therefore, it is beneficial to recommend exercise as part of cardio-oncology preventive care. With the progress of deep learning algorithms and the improvement of big data processing techniques, artificial intelligence (AI) has gradually become popular in the fields of medicine and healthcare. In the context of the shortage of medical resources in China, it is of great significance to adopt AI and machine learning methods for prescription recommendations. This study aims to develop an interpretable machine learning-based intelligent system of exercise prescription for cardio-oncology preventive care, and this paper presents the study protocol. This will be a retrospective machine learning modeling cohort study with interventional methods (i.e., exercise prescription). We will recruit PLWC participants at baseline (from 1 January 2025 to 31 December 2026) and follow up over several years (from 1 January 2027 to 31 December 2028). Specifically, participants will be eligible if they are (1) PLWC in Stage I or cancer survivors from Stage I; (2) aged between 18 and 55 years; (3) interested in physical exercise for rehabilitation; (4) willing to wear smart sensors/watches; (5) assessed by doctors as suitable for exercise interventions. At baseline, clinical exercise physiologist certificated by the joint training program (from 1 January 2023 to 31 December 2024) of American College of Sports Medicine and Chinese Association of Sports Medicine will recommend exercise prescription to each participant. During the follow-up, effective exercise prescription will be determined by assessing the CVD status of the participants. This study aims to develop not only an interpretable machine learning model to recommend exercise prescription but also an intelligent system of exercise prescription for precision cardio-oncology preventive care. This study is approved by Human Experimental Ethics Inspection of Guangzhou Sport University. http://www.chictr.org.cn, identifier ChiCTR2300077887.